MPI 1121
Alternative Names: MPI-1121Latest Information Update: 17 Sep 2021
At a glance
- Originator Texas A&M University
- Developer Sorrento Therapeutics
- Class Amides; Amines; Antivirals; Ketones; Peptidomimetics; Pyrrolidines; Small molecules
- Mechanism of Action Cathepsin L inhibitors; Coronavirus-3C-like-proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 13 Sep 2021 Preclinical trials in COVID-2019 infections (Prevention) in USA (PO) prior to September 2021
- 13 Sep 2021 Preclinical trials in COVID-2019 infections in USA (PO) prior to September 2021
- 26 Aug 2021 Sorrento Therapeutics in-licenses main protease inhibitors for COVID-2019 infections from Texas A&M University